Trials / Recruiting
RecruitingNCT05824585
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Dizal Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586. |
Timeline
- Start date
- 2023-05-15
- Primary completion
- 2027-04-30
- Completion
- 2027-10-30
- First posted
- 2023-04-21
- Last updated
- 2025-08-11
Locations
5 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05824585. Inclusion in this directory is not an endorsement.